Ethnic disparities in cardiovascular and renal responses to canagliflozin between Asian and White patients with type 2 diabetes mellitus: A post hoc analysis of the CANVAS Program
Authors' conclusion
Canagliflozin reduced CV and renal risks similarly in Whites and Asians; however, there was a significant racial discrepancy in all-cause mortality. This distinction may be attributed to the fact that Asian patients exhibited diminished CV protection effects and more renal adverse events with canagliflozin, potentially resulting from the smaller reductions in weight and uric acid. These findings highlight the importance of investigating the impact of race on treatment response to sodium-glucose cotransporter-2 inhibitors and provide more precise treatment strategies.
Study context
- Population
- Patients with T2D enrolled in the CANVAS Program
- Participants
- 10,142 patients
- Comparison
- Canagliflozin effects in White vs Asian patients
Methodological detailssubgroup analysis by race, treatment-race interaction
- Subgroup analysis by race
- Treatment-race interaction
Primary result
As reported in the abstract
All-cause mortality, canagliflozin effect by race
| Group | HR |
|---|---|
| Whites | 0.84 (95% CI 0.71-0.99) |
| Asians | 1.64 (95% CI 0.94-2.90) |
HR
Whites0.84 (95% CI 0.71-0.99)
Asians1.64 (95% CI 0.94-2.90)
- Whites vs Asians: P = 0.04
Further findings
| Outcome | P value |
|---|---|
| Composite of hospitalization for HF and CV deathMarginally significant | P = 0.06 |
Safety
| Outcome | P value |
|---|---|
| Acute kidney injurySignificant | P = 0.04 |
| Serious renal-related adverse eventsMarginally significant | P = 0.07 |
Original publication
Ethnic disparities in cardiovascular and renal responses to canagliflozin between Asian and White patients with type 2 diabetes mellitus: A post hoc analysis of the CANVAS Program. Diabetes Obes Metab. Published 30 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →